Phase 1 trial of intranasal NDV-HXP-S in previously vaccinated adults
Vaccine. 2026 Jun 30;89:128870. doi: 10.1016/j.vaccine.2026.128870. Online ahead of print.
PMID:
The role of mucosal IgA in protection against influenza A H1N1 virus infection in a real-world setting
EBioMedicine. 2026 Jul;129:106359. doi: 10.1016/j.ebiom.2026.106359. Epub 2026 Jun 30.
PMID:
Nur77 agonism invigorates Natural Killer cell immunity against hepatocellular carcinoma
Nat Commun. 2026 Jun 30. doi: 10.1038/s41467-026-75027-3. Online ahead of print.
PMID:
mRNA-based influenza vaccine expands the B cell response breadth in humans
Nat Immunol. 2026 Jun 15. doi: 10.1038/s41590-026-02569-5. Online ahead of print.
PMID:
Seasonal vaccine-induced immunity shows preserved cross-reactivity to H3N2 subclade K in adults
EBioMedicine. 2026 Jun 12;129:106321. doi: 10.1016/j.ebiom.2026.106321. Online ahead of print.
PMID:
Vaccines and therapeutics for Andes hantavirus
Npj Viruses. 2026 Jun 9;4(1):29. doi: 10.1038/s44298-026-00200-w.
PMID:
Andes hantavirus – A primer
Npj Viruses. 2026 Jun 5;4(1):27. doi: 10.1038/s44298-026-00201-9.
PMID:
Seroprevalence of IgM and IgG Antibodies Directed Against Hepatitis E Virus in 4867 Blood Donors From Tyrol, Austria
J Med Virol. 2026 Jun;98(6):e70991. doi: 10.1002/jmv.70991.
PMID:
Privacy-Preserving Self-Registration to a Large-Scale Randomised Controlled Clinical Screening Trial in Austria
Stud Health Technol Inform. 2026 May 21;336:1875-1879. doi: 10.3233/SHTI260563.
PMID:
Cross-reactive human antibody responses to H9N2 influenza virus, New York, United States, 2025
Euro Surveill. 2026 May;31(20):2600375. doi: 10.2807/1560-7917.ES.2026.31.20.2600375.
PMID: